Reviewing the news that Sanofi will exit the OTC market after setting up its Consumer Healthcare business to go it alone.
Analysts at the major investment banks are generally in agreement with Sanofi CEO Paul Hudson’s assessment of the firm’s Consumer Healthcare (CHC) separation plan as a “win win.”
“Our early take on these strategic actions is that the separation of CHC is the right thing to do strategically,” said Barclays’ Emily Field, while HSBC’s Rajesh Kumar and Jefferies’ Peter Welford separately noted the decision had been eagerly
Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.
A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.
US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.
CRN/Radicle Science expand Trailblazer Award nominations; BodyArmor brand relaunch with ‘Choose Better’ campaign and pro athletes; and Just Ingredients catches Bryce Harper as partner.
Amazon executive moves Hims & Hers; INW Manufacturing adds IPA board member as CSO; USC Gerontology School dean joins Niagen advisory board; ‘Be You, NOW’ campaign during Women’s Health Month; direct seller Tranont expands advisory board; Vitamin Shoppe, sports nutrition brands support Team Red, White & Blue cross-US runners; and Powerade supports Morgan's Message.
C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.
Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.
